MedTrace Logo

Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

NCT06963814 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2025-07-17

No results posted yet for this study

Summary

This is an open-label, multicenter Phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HC006 in combination with a PD-1 inhibitor in patients with advanced solid tumors. The trial is divided into two stages: dose-escalation and dose expansion. First, the dose-escalation study is completed to determine the recommended dose for subsequent extension studies, and then the dose expansion study is conducted in the proposed tumors with potential treatment benefits.

Conditions

Interventions

DRUG

HC006

Specified dose on specified days

DRUG

KEYTRUDA ®( Pembrolizumab)

Specified dose on specified days

Sponsors & Collaborators

  • HC Biopharma Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-04
Primary Completion
2026-05-30
Completion
2027-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06963814 on ClinicalTrials.gov